The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania

The Burden of (Neuro)Cysticercosis Among People Living With HIV Compared With HIV-negative Individuals in the Rural Southern Highlands in Tanzania

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03851419

Acronym

CYSTINET_Tz

Enrollment

2584

Registered

2019-02-22

Start date

2018-04-01

Completion date

2021-04-30

Last updated

2023-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS, Neurocysticercosis

Brief summary

This study aims to compare the burden of neurocysticercosis among people living with HIV to people not infected with HIV.

Detailed description

People living with HIV and matched HIV negative controls will be tested serologically for cysticercosis, examined neurologically and will undergo CT scanning to determine the prevalence and presentation of NCC. Furthermore, the immune system response in HIV patients with Taenia solium neurocysticercosis will be assessed.

Interventions

DIAGNOSTIC_TESTDiagnosis of (Neuro)cysticercosis

* Serological tests for cysticercosis * Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis * Stool testing for T. solium

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

14 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients who consent to participate in the study and testing. * Patients of age 14 years and above * Patient living inside the study catchment area * HIV-positive patients * Patient suspected of taeniasis or cysticercosis/neurocysticercosis

Exclusion criteria

* Patients with opportunistic infections. * Study participants taking anthelminthic drugs PZQ and ALB or have received them within the previous 12 months. * Pregnant women * Patients that are seriously ill. * Patients with epilepsy and other mental disorders that impair thoughts and emotions such as psychosis.

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of cysticercosis	Single assessment at inclusion into study (serological testing)	Prevalence of cysticercosis among people living with HIV and matched HIV-negative individuals in rural Tanzania where pig farming is common
Prevalence of neurocysticercosis	Single assessment through cerebral CT scan at inclusion into study	Prevalence of neurocysticercosis among people living with HIV and matched HIV-negative individuals in rural Tanzania where pig farming is common

Secondary

Measure	Time frame	Description
Th1 cytokines among neurocysticercosis patients	One time assessment through immunological testing at inclusion into study	To compare the specific peripheral immune response against T. solium neurocysticercosis between symptomatic and asymptomatic patients measured by concentration of Th1 cytokines.

Countries

Tanzania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026